JP2022546400A5 - - Google Patents
Info
- Publication number
- JP2022546400A5 JP2022546400A5 JP2022513090A JP2022513090A JP2022546400A5 JP 2022546400 A5 JP2022546400 A5 JP 2022546400A5 JP 2022513090 A JP2022513090 A JP 2022513090A JP 2022513090 A JP2022513090 A JP 2022513090A JP 2022546400 A5 JP2022546400 A5 JP 2022546400A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- liquid formulation
- approximately
- formulation according
- stabilized liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921035059 | 2019-08-30 | ||
| IN201921035059 | 2019-08-30 | ||
| PCT/IB2020/058080 WO2021038532A1 (en) | 2019-08-30 | 2020-08-29 | Novel formulation of highly concentrated pharmacologically active antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546400A JP2022546400A (ja) | 2022-11-04 |
| JP2022546400A5 true JP2022546400A5 (cg-RX-API-DMAC7.html) | 2023-11-24 |
| JP7792137B2 JP7792137B2 (ja) | 2025-12-25 |
Family
ID=74684124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513090A Active JP7792137B2 (ja) | 2019-08-30 | 2020-08-29 | 高濃度の薬理学的に活性な抗体の新規製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220267473A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021497B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7792137B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020337093B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152838A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3071089T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021038532A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| CA3237624A1 (en) * | 2023-07-28 | 2025-04-24 | Genentech, Inc. | NEW USES FOR OMALIZUMAB |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60139944D1 (de) * | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20140186361A1 (en) * | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| CA2690382A1 (en) | 2007-06-14 | 2008-12-24 | Biogen Idec Ma Inc. | Antibody formulations |
| SG10201500871TA (en) * | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| AR089434A1 (es) * | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| KR20160105535A (ko) | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| JP2016515120A (ja) | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防 |
| RS57864B1 (sr) * | 2013-06-17 | 2018-12-31 | De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo | Postupci za sprečavanje agregacije virusnih komponenti |
| JP2018500380A (ja) | 2014-12-31 | 2018-01-11 | ノベルメド セラピューティクス,インコーポレーテッド | アグリコシル化治療用抗体の製剤 |
| US10994011B2 (en) | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| ES2965486T3 (es) | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
-
2020
- 2020-08-29 JP JP2022513090A patent/JP7792137B2/ja active Active
- 2020-08-29 CA CA3152838A patent/CA3152838A1/en active Pending
- 2020-08-29 ES ES20858260T patent/ES3071089T3/es active Active
- 2020-08-29 AU AU2020337093A patent/AU2020337093B2/en active Active
- 2020-08-29 EP EP20858260.1A patent/EP4021497B1/en active Active
- 2020-08-29 WO PCT/IB2020/058080 patent/WO2021038532A1/en not_active Ceased
-
2022
- 2022-02-28 US US17/682,314 patent/US20220267473A1/en active Pending
-
2024
- 2024-10-25 US US18/926,965 patent/US20250043027A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12296008B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| JP7112327B2 (ja) | ベバシズマブの緩衝された製剤 | |
| JP2023055780A5 (cg-RX-API-DMAC7.html) | ||
| JP7473603B2 (ja) | 液体医薬組成物 | |
| JP2019536761A5 (cg-RX-API-DMAC7.html) | ||
| Hufnagel et al. | Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying | |
| JP2021155453A5 (cg-RX-API-DMAC7.html) | ||
| JP2022166006A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500360A5 (cg-RX-API-DMAC7.html) | ||
| JP7089121B2 (ja) | 高濃度の抗vegf抗体を含有するタンパク質溶液製剤 | |
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| JP2018512391A5 (cg-RX-API-DMAC7.html) | ||
| PE20091327A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| JP2013500947A5 (cg-RX-API-DMAC7.html) | ||
| JP2013543505A5 (cg-RX-API-DMAC7.html) | ||
| HRP20250830T1 (hr) | Farmaceutski pripravak s niskim ph koji sadrži konstrukte protutijela koja djeluju na t-stanice | |
| MA62173B1 (fr) | Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation | |
| JP2016515124A5 (cg-RX-API-DMAC7.html) | ||
| JP2021521159A5 (cg-RX-API-DMAC7.html) | ||
| RU2011140498A (ru) | Препарат антител | |
| JP2021521171A5 (cg-RX-API-DMAC7.html) | ||
| CN107249639A (zh) | 联用药物 | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| JP2021501213A5 (cg-RX-API-DMAC7.html) |